Medindia

X

BIO 2008: Germany on Cutting Edge in Biomanufacturing

Thursday, June 19, 2008 General News J E 4
Advertisement
SAN DIEGO, California, June 18 Germany is on the cuttingedge in biotechnology R&D and is a top player in large- and clinical-scaleproduction. Companies located in Germany are poised to profit from the latestdevelopments in biomanufacturing. These were the results of an expert panel,at the BIO International Convention (BIO 2008) in San Diego, California onJune 18th. Invest in Germany co-chaired the panel along with the CEO of amajor transatlantic biotech consultancy.

Dr. Barbara Esch opened the discussion, entitled "BiomanufacturingSolutions: Case Studies from Germany." She is responsible for the businessdevelopment of biopharmaceuticals in the Corporate DivisionBiopharmaceuticals at the Boehringer Ingelheim GmbH in Ingelheim, Germany.Her presentation provided an overview of the biotechnology market in Germany,and offered examples of leading investment successes in Germany. Dr. WiltrudTreffenfeldt, Director of Bioprocess Development, Dow AgroSciences LLC,discussed why the German contract manufacturing industry is uniquelypositioned to create sustainable value in biopharmaceutical development andsupply. Dr. Uwe Marx, Chief Scientific Officer (CSO) of Probiogen, aBerlin-based company that specializes in mammalian cell engineering and cellculture, discussed clinical biomanufacturing and how it serves the diverseneeds of his company's client base.

Lastly Dr. Uwe Gottschalk, Vice President of Purification Technologies atSartorius AG, talked about his perception of the current trends inbiomanufacturing from the focus of an internationally leading processtechnology provider.

Angelika Geiger, Director of Invest in Germany's San Francisco office,and Steven Dickman, CEO of CBT Advisors chaired the panel. CBT Advisors is aninternational strategic consultancy with a focus on European and Americanbiotech companies. Mr. Dickman also has experience in Germany. He previouslydid biochemical research at the German Cancer Research Center and served ascorrespondent for the journal Nature in Germany.

Invest in Germany is the inward investment promotion agency of theFederal Republic of Germany. It provides investors with comprehensive supportfrom site selection to the implementation of investment decisions. Invest inGermany is at booth 711 throughout BIO 2008.Eva Henkel Invest in Germany Phone: +49-30-200099-173 email: henkel@invest-in-germany.com http://www.invest-in-germany.com

SOURCE Invest in Germany
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
BIO 2008: Germany on Cutting Edge in Biomanufactur...
S
ACTS Retirement-Life Communities Signs Land Purcha...